Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome

Endocrine Reviews

Volumn 21, Issue 6, 2000, Pages 697-738

  Wajchenberg, B L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOKINE; ESTROGEN; GLUCOSE; GROWTH HORMONE; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINOID; TESTOSTERONE; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; BODY FAT; CONTROLLED STUDY; CUSHING SYNDROME; ENERGY BALANCE; FEMALE; GLUCOSE METABOLISM; HORMONAL REGULATION; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIPODYSTROPHY; LIPOGENESIS; LIPOLYSIS; MALE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SECRETION; REVIEW; SUBCUTANEOUS TISSUE; TISSUE DISTRIBUTION;

EID: 0034504237     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.21.6.0415     Document Type: Review

References (361)

1. Epidemiology of obesity in relation to health hazards
2. Lipids, diabetes and coronary heart disease: Insights from the Framingham Study
3. Overweight, obesity, coronary heart disease and mortality
4. The influence of obesity and health: Part 2
5. Obesity, fat distribution and cardiovascular disease
6. La differénciation sexuelle, facteur determinant des formes de l'obésité
7. Genetic and nongenetic determinants of regional fat distribution
8. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913
9. Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow-up of participants in the population study of women in Gothenburg, Sweden
10. The independent contributions of various indices of obesity to the 22-year incidence of coronary heart disease: The Framingham Heart Study
11. The pattern of subcutaneous fat distribution in middle-aged men and risk of coronary heart disease: The Paris Prospective Study
12. Central obesity and coronary heart disease in men
13. The influence of body fat distribution on the incidence of diabetes mellitus - 13.5 years of follow-up of the participants in the study of men born in 1913
14. Endrocrine characteristics in regional obesities: Role of sex steroids
15. Hazards in subgroups of human obesity
16. Obesity and the risk of cardiovascular disease
17. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity
18. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women
19. Visceral obesity in men. Associations with glucose tolerance, plasma insulin and lipoprotein levels
20. Intra-abdominal fat is associated with decreased insulin sensitivity in healthy young men
21. The morphology and metabolism of intraabdominal adipose tissue in men
22. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease
23. Obesity and lipid metabolism: Relevance of body fat distribution
24. Lipoprotein metabolism in visceral obesity
25. Lipoprotein metabolism in diabetes mellitus
26. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degress of glucose tolerance
27. Visceral obesity and dyslipidemia: Contribution of insulin resistance and genetic susceptibility
28. Genetic aspects of susceptibility to obesity and related dyslipidemias
29. Abdominal obesity as an important component of insulin resistance syndrome
30. Relationships of generalized and regional adiposity to insulin sensitivity in men
31. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat
32. Visceral adipose tissue: A critical review of intervention strategies
33. Metabolic implications of body fat distribution
34. Endocrine abnormalities in obesity
35. Estimarion of adipose tissue mass by magnetic resonance imaging: Validation against dissection in human cadavers
36. Central obesity: Measurement and metabolic effects
37. Subcutaneous fat distribution during growth
38. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women
39. Treatment of obesity: An overview
40. Measurement of fat distribution
41. Obesity: New insight into the anthropometric classification of fat distribution shown by computed tomography
42. Assessment of adipose tissue distribution by computed axial tomography in obese women: Association with body density and anthropometric measurements
43. The sagittal diameter is a valid marker of the visceral adipose tissue volume
44. Abdominal fat depots measured by computed tomography: Effects of degree of obesity, sex, and age
45. Estimation of deep abdominal adipose tissue accumulation from simple anthropometric measurements in men
46. The influences of height and age on waist circumferences as an index of adiposity in adults
47. Waist circumference as a measure for indicating need for weight management
48. Waist circumference reduction and cardiovascular benefits during weight reduction in women
49. Race-dependent health risks of upper body obesity
50. Computed axial tomography scan measurement of abdominal fat distribution and its correlation with anthropometry and insulin secretion in health Asian Indians
51. The visceral adiposity syndrome in Japanese-American men
52. Metabolic consequences of obesity and body fat pattern: Lessons from migrant studies
53. Is abdominal body fat distribuition a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Göteborg, Sweden
54. Waist circumference action levels in the identification of cardiovascular risk factors: Prevalence study in a random sample
55. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: Predictive equations
56. Abdominal diameters as indicators of visceral fat: Comparison between magnetic resonance imaging and anthropometry
57. Assessment of abdominal distribution in obese patients: Anthropometry vs. computerized tomography
58. Are Abdominal diameters abominable indicators?
59. Adipose tissue distribution measured by magnetic resonance imaging in obese women
60. The sagittal waist diameter and mortality in men: The Baltimore Longitudinal Study on Aging
61. A multicompartment body composition technique based on computorized tomography
62. A multicompartment body composition technique based on computerized tomography
63. Quantification of adipose tissue by MRI: Relationship with anthropometric variables
64. 40K and tritium
65. Adipose tissue volume determinations in women by computed tomography: Technical considerations
66. Assessment of abdominal fat content by computed tomography
67. A novel technique for determination of body fat by computed tomography
68. Subcutaneous and visceral fat distribution according to sex, age and overweight, evaluated by computed tomography
69. CT-determined changes in adipose tissue distribution during a small weight reduction in obese males
70. Body fat distribution measured with CT: Correlations in healthy subjects, patients with anorexia nervosa and patients with Cushing's syndrome
71. Methodological and clinical aspects of subcutaneous fat distribution
72. Reproducibility of computed tomography measurement of visceral adipose tissue area
73. Effects of diet and physical activity on adiposity and body fat distribution: Implications for the prevention of cardiovascular disease
74. Intra-abdominal adipose tissue variables associated with risk of possessing elevated blood lipids and blood pressure
75. Intra-abdominal adipose tissue cut points related to elevated cardiovascular risk in women
76. A single threshold value of waist girth indentifies normal weight and overweight subjects with excess visceral adipose tissue
77. Visceral fat and cardiovascular risk factors in chinese NIDDM patients
78. Visceral fat accumulation and cardiovascular disease
79. Contribution of visceral fat accumulation to postprandial hyperlipidemia in human obesity
80. Effect of fat distribution on pharmocokinetics of cortisol in obesity
81. Techniques for the measurement of visceral fat: A predicted guide
82. Evaluation of a new magnetic resonance imaging method for quantitating adipose tissue areas
83. Total and intra-abdominal fat measurements by ultrasound and computerized tomography
84. Anthropometric or ultrasonic measurements in assessment of visceral fat? A comparative study
85. The contribution of sonography to the measurement of intra-abdominal fat
86. Sonography detection of small intra abdominal fat variations
87. Measured and predicted total and visceral adipose tissue in women. Correlations with metabolic parameters
88. Age changes in body composition revealed by computed tomography
89. Total and subcutaneous adipose tissue in women: The measurement of distribution and accurate prediction of quantity by using magnetic resonance imaging
90. Regional obesity
91. Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue?
92. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness
93. Postprandial triglyceride response in visceral obesity in men
94. The response to long-term overfeeding in identical twins
95. Effect of weight loss on regional body fat distribution in premenopausal women
96. High adipose tissue lipoprotein lipase activity plays a causal role in the etiology of obesity
97. Peripheral triglyceride clearance, the Adipsin-ASP pathway and Type IV hyperlipoproteinemia
98. Metabolism of adipose tissue in intraabdominal depots of non-obese men and women
99. Metabolism of adipose tissue in intraabdominal depots in severely obese men and women
100. Glucose and free fatty acid metabolism in human obesity. Relationships to insulin resistance
101. Expression of lipoprotein lipase in different human subcutaneous adipose tissue regions
102. The effects of weight loss on the activity and expression of adipose-tissue lipoprotein lipase in very obese humans
103. Adrenergic regulation of adipocyte metabolism
104. 3-adrenoceptor in man
105. 3-adrenoceptor in man
106. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells
107. β-Adrenoceptor expression in human fat cells from different regions
108. 3-adrenoreceptors in obesity
109. 3-adrenoceptor sensitivity in visceral adipose tissue
110. Increased insulin resistance and fat cell lipolysis in obese but not lean women with high waist/hip ratio
111. Regional variation in adipose tissue metabolism of severely obese premenopausal women
112. 2-adrenoceptors
113. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes
114. Sex differences in visceral fat lipolysis and metabolic complications of obesity
115. Glucocorticoid hormone binding to human adipose tissue
116. The adipose tissue metabolism: Role of testosterone and dehydroepiandrosterone
117. Long-term testosterone administration increases visceral fat in female to male transsexuals
118. Induction of insulin resistance by androgens and estrogens
119. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
120. Identification of estrogen receptor in human adipose tissue and adipocytes
121. Steroid hormone receptors in human adipose tissue
122. Receptors in human adipose tissue
123. Fat cell adrenergic receptors and the control of white and brown fat cell function
124. Nuclear triiodothyronine receptor of human adipose tissue
125. Different metabolic regulation by adenosine in omental and subcutaneous adipose tissue
126. A-1 adenosine receptors in human fat cell: Tissue distribution and regulation of radioligand binding
127. Prostagladin E 2, action and binding in human adipocytes: Effects of sex, age, and obesity
128. Familial aggregation of abdominal visceral fat: Results from the Quebec Family Study
129. L'épidémiology génétique et la génétique moléculaire de l'obésité: Les enseignements de l'étude des families de Quebec
130. Familial resemblance for abdominal visceral fat: The HERITAGE Family Study
131. Major gene for abdominal visceral fat area in the Quebec Family Study
132. Segregation analysis of abdominal visceral fat: The HERITAGE Family Study
133. Segregation analysis of fat mass and other body composition measures derived from underwater weighing
134. Familial clustering of abdominal visceral fat and total fat mass: The Quebec Family Study
135. The response to exercise with constant energy intake in identical twins
136. The human obesity gene map: The 1997 update
137. DNA sequence variation in the lipoprotein lipase (LPL) gene and obesity
138. DNA variation in the genes of the Na, K-adenosine triphosphatase and its relation with resting metabolic rate, respiratory quotient, and body fat
139. Association of a polymorphism in the β3-adrenergic receptor gene with features of the insulin resistance syndrome in Finns
140. Genetic variation in the β3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity
141. A mutation of the β3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride
142. The lipoprotein lipase HindIII polymorphism modulates plasma triglyceride levels in visceral obesity
143. ApoB-100 gene EcoRI polimorphism. Relations to plasma lipoprotein changes associated with abdominal visceral obesity
144. Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus
145. Linkage between human synthetic region to the mouse Mob-1 QTL and abdominal visceral fat and blood lipids
146. The putative role of the hormone-sensitive lipase gene in the pathogenesis of Type II diabetes mellitus and abdominal obesity
147. L'adipocyte, cellule sécrétice et endocrine
148. Depot-related gene expression in human subcutaneous and omental adipocytes
149. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men
150. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis
151. Regional differences in triacyglycerol synthesis in adipose tissue
152. Secretion of cholesteryl ester transfer protein by adipose tissue
153. Plasma cholesterely ester transfer protein
154. Effect of adiposity on plasma lipid transfer protein activities: A possible link between insulin resistance and high density lipoprotein metabolism
155. Increased plasma cholesteryl ester trasnfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity
156. Increased plasma cholesteryl ester transfer activity in obese children
157. Retinoids and retinoid-binding protein expression in rat adipocytes
158. Regulation of adipocyte gene expression by retinoic acid and hormones: Effects on the gene encoding cellular retinol-binding protein
159. Retinyl ester hydrolysis and retinol efflux from BFC-1 β adipocytes
160. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease 1996
161. Production of Plasminogen activator inhibitor-1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
162. Visceral fat as a main determinant of plasminogen activator inhibitor-1 level in women
163. Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by human hepatocellular cell line Hep 62
164. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells
165. Plasminogen activator inhibitor type 1 synthesis and mRNA expression in Hep G2 cells are regulated by VLDL
166. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells
167. Short-term infusions of insulin, triacyglycerol and glucose do not cause acute increases in Plasminogen activator inhibitor-1 concentrations in man
168. Synergistic augmentation of expression of Plasminogen activator inhibitor type 1 induced by insulin, very low density lipoproteins and fatty acids
169. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases Plasminogen activator inhibitor-1 in blood of normal human subjects
170. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
171. Plasminogem activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
172. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
173. Corticosteroids and insulin affect PAI-1 synthesis by human adipose tissue
174. PAI-1 antigen production by human adipose tissue is correlated with that of TNF-α
175. Pharmacology of estrogens
176. Effects of aging and obesity on aromatase activity of human adipose cells
177. Competitive reverse transcription polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs and abdomen of women increase with advancing age
178. Androgen-estrogen metabolism in women with upper body vs. lower body obesity
179. Increased estrogen production in obese men
180. Reduced testosterone and adrenal C19 steroid levels in obese men
181. Widespread tissue distribution of steroid sulfatase, 3β-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3β-HSD), 17β-HSD, 5αreductase, and aromatase activities in the rhesus monkey
182. Adipose tissue as as source of hormones
183. Male and female diversity in regulation of aromatase activity by insulin and glucocorticoid in human adipose tissue
184. Positional cloning of the mouse obese gene and its human homologue
185. Weight-reducing effects of the plasma protein encoded by the obese gene
186. Leptin and the regulation of body adiposity. A critical review
187. Leptin: The tale of an obesity gene
188. Leptin levels in human and rodent: Measurement of plasma leptin and obRNA in obese and weight-reduced subjects
189. Depot- and sex-specific differences in human leptin mRNA expression: Implications for the control of regional fat distribution
190. Increved obese mRNA expression in omental fat cells from massively obese humans
191. Leptin: Its role in obesity and beyond Diabetologia
192. Leptin secretion from subcutaneous and visceral adipose tissue in women
193. Evidence for leptin binding to proteins in serum of rodents and humans: Modulation with obesity
194. Response to leptin to short-term and prolonged overfeeding in humans
195. Effects of fasting and refeeding on ob gene expression in white adipose tissue of lean and obese mice
196. Effect of fasting on serum leptin in normal human subjects
197. Expression of ob gene in adipose cells: Regulation by insulin
198. Transient increase in obese gene expression after food intake or insulin administration
199. Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: Increased responsiveness to glucocorticoids in obesity
200. Physiological insulinemia acutely modulates plasma leptin
201. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals
202. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes
203. Leptin concentrations in relation to body mass index and the tumor necrosis factor-α system in humans
204. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight
205. Direct antidiabetic effect of leptin through triglyceride depletion of tissues
206. β-Cell function in normal rats made chronically hyperleptinemic by adenovirus-leptin gene therapy
207. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of Adipogenic diabetes mellitus
208. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells
209. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II
210. In vivo angiotensinogen gene expression in rat adipocytes: Regional specificities and regulation by androgens
211. Developmental changes in angiotensinogen expression and its secretion in the Zucker rat: Adipose tissue-specific effect of FA genotype
212. Gene expression of angiotensinogen in adipose tissue of obese patients
213. A novel adipocyte-derived factor, adiponectin, inhibits growth of vascular smooth muscle cell
214. A novel adipocyte-derived factor, adiponectin, is decreased in obesity and coronary artery disease
215. Analysis of plasma adiponectin and leptin levels in rhesus monkeys
216. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase
217. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance
218. Elevated tumor necrosis factor-α in sera of obese patients: Fall with weight loss
219. Tumor necrosis factor-alpha as a mediator of insulin resistance
220. Transcriptional repression of the GLUT 4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-α
221. Interferons and tumor necrosis factors have similar catabolic effects on 3T3-L1 cells
222. Through thick and thin: Wasting, obesity, and TNF-α
223. Evidence for a role of tumor necrosis factor-α in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease
224. The subcutaneous adipose tissue expression of the TNF-α is not related to obesity or insulin resistance in humans
225. Depot differences in the regulation of adipocyte secretory products in human adipose tissue: The examples of lipoprotein lipase and leptin
226. PPAR-γ adipogenic regulator and thiazolidinedione receptor
227. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
228. Depot-specific differences in adipose tissue gene expression in lean and obese subjects
229. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss and regulation by insulin and glucocorticoids
230. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alterations in adipose tissue of obese and NIDDM patients
231. PPAR γ, versatile metabolic regulator. 33th Minkowsky Lecture
232. Elevation of plasma cytokines in disorders of excessive daytime sleepeness: Role of sleep disturbance and obesity
233. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid
234. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: Expression and effects on steroidogenesis
235. Interleukin-6 stimulates hepatic triglyceride secretion in rats
236. Expression of Insulin-like growth factor-1 (IGF-1), IGF-1 receptor and IGF-binding protein-3 in human adipocyte precursor cells during differentiation
237. Regulation of insulin-like growth factor-1 expression in mouse preadipocyte Ob1771
238. Les protéines découplantes mitochondriales
239. Uncoupling protein- 1 mRNA expression: Relation to obesity and sequence variations at the UCP-1 gene locus
240. 3-adrenergic receptor gene on weight loss in moderate obesity
241. Reduced UCP-2 mRNA expression levels in intraperitoneal adipose tissue of obese humans
242. Reduced gene expression of UCP-2 but not UCP-3 in skeletal muscle of human obese subjects
243. Biosynthesis of the vasoactive lipid monobutyrin
244. Not all fat is alike
245. Effects of body fat distribution on regional lipolysis in obesity
246. Regional postprandial fatty acid metabolism in different obesity phenotypes
247. Biology of regional fat distribution: Relationship to non-insulin-dependent diabetes mellitus
248. Risk factors in obese women, with particular reference to visceral fat component
249. Dyslipidemia of central obesity and insulin resistance
250. Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat adipocytes
251. Effect of fatty acids on glucose production and utilization in men
252. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects
253. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
254. Syndrome X: A syndrome of insulin resistance. Epidemiological and clinical evidence
255. The glucose-fatty acid cycle in obesity and maturity-onset diabetes mellitus
256. The effect of noninsulin-dependent diabetes mellitus and obesity on glucose trans sport and phosphorylation in skeletal muscle
257. Mechanism of free fatty acid-induced insulin resistance in humans
258. Intramuscular triglyceride and muscle insulin sensitivity: Evidence for a relationship in non diabetic subjects
259. Lipotoxicity in the pathogenesis of obesity-dependent non-insulin dependent diabetes mellitus. Genetic and clinical implications
260. Tissue triglycerides, insulin resistance, and insulin production: Implications for hyperinsulinemia in obesity
261. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non-diabetic subjects
262. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and non-diabetic subjects
263. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes
264. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans
265. Skeletal muscle capillary density and fiber type are possible de-terminants of in vivo insulin resistance in man
266. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women
267. Insulin resistance and its relationship to different obesity phenotypes
268. Protein metabolism in human obesity: Relationship with glucose and lipid metabolism and with visceral adpose tissue
269. Relationship of visceral adipose tissue and glucose disposal is independent of sex, in black NIDDM subjects
270. Quantitative estimation of insulin sensitivity
271. Estimation of β-cell sensitivity from IVGTT C-peptide data. Knowledge of the kinetics avoids errors in modeling secretion
272. Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity
273. Splanchnic insulin metabolism in obesity: Influence of body fat distribution
274. Effects of free fatty acids and glucose on splanchnic insulin dynamics
275. The "metabolically-obese", normal-weight individual
276. Banting Lecture: Role of insulin resistance in human disease
277. Insulin resistence in obese and non-obese men
278. The metabolicaly obese, normal-weight-weight individual revisited
279. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance
280. Risk factors for coronary heart disease in healthy subjects with hyperinsulinemia and normal glucose tolerance
281. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men
282. Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk
283. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women
284. Insulin resistence in aging is related to abdominal obesity
285. Type 2 (non-Insulin-dependent) diabetes mellitus, hypertension and hyperlipidemia (Syndrome X): Relation to reduced fetal growth
286. Thinness at birth and insulin resistance in adult life
287. Birthweight and adult health outcomes in a biethnic population in the USA
288. Insulin sensitivity, glucose effectiveness and body fat distribution pattern un nondiabetic offspring of patients with NIDDM
289. Effects of body composition and exercise capacity on glucose tolerance, insulin and lipoprotein lipids in healthy older men
290. Ten year experience with an exercise-based out patient lifestyle modification program in the treatment of diabetes mellitus
291. Insulin resistance in relatives of NIDDM patients: The role of physical fitness and muscle metabolism
292. Increased glucose transport phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects
293. Genetics of obesity
294. Exercise and the metabolic syndrome
295. Low-intensity endurance training, plasma lipoproteinas and the risk of coronary heart disease
296. 2 max
297. Subcutaneous and visceral fat distribution and daily physical activity: Comparison between young and middle aged women
298. Effects of diet-and exercise-induced weight loss on visceral adipose tissue in men and women
299. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
300. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men
301. Do elevated levels of abdominal visceral adipose tissue contribute to age-related differences in plasma lipoprotein concentrations in men?
302. Adipose tissue distribution and plasma lipoprotein levels in obese women: Importance of intra-abdominal fat
303. Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue?
304. Weekly clinicopathologic exercises. Case 1-1975
305. Clinical Case Seminar. Postmortem findings in congenital generalized lipodystrophy
306. Peculiar distribution of adipose tissue in patients with gongenital generalized lipodystrophy
307. Generalized lipodystrophy, congenital and acquired (lipoatrophy)
308. Estimation of body fat and lean tissue distribution by dual energy x-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease
309. Skeletal muscle triglyceride levels are inversely related to insulIn action
310. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women
311. Intramuscular lipid is increased in subjects with congenital generalized lipodystrophy
312. 1H spectroscopy: Validation in vivo
313. Changes in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus
314. Changes in lipolytic enzymes duster with insulin resistance syndrome
315. Review. Fatty acids, lipotoxicity and insulin secretion
316. Islet amyloid. A long-recognized but underappreciated pathological feature of type 2 diabetes
317. Genetic exclusion of 14 candidate genes in Lipoatropic diabetes using linkage analysis in 10 consanguineous families
318. A gene for congenital generalized lipodystrophy to human chromosome 9q34
319. Cortisol secretion in relation to body fat distribution in obese premenopausal women
320. Does central obesity reflect "Cushing's disease of the omentum"?
321. Obesity and gender influence cortisol secretion and metabolism in man
322. Visceral obesity: A condition of altered hypothalamic-pituitary-adrenocortical (HPA) axis function?
323. The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribuition
324. Stress-induced cortisol response and fat distribution in women
325. Hypothalamic-pituitary-adrenal axis activity and is relationship to the autonomic nervous system in women with visceral obesity and subcutaneous obesity: Effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress
326. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: A dose-response study
327. Growth hormone axis in Cushing's syndrome
328. Visceral fat accumulation in men is positively associated with insulin glucose and C-peptide levels, but negatively with testoterone levels
329. Obesity, body fat distribution and sex hormones in men
330. The relationship of sex hormones to hyperinsulinemia and hyperglycemia
331. The relationship between insulin-like growth factor 1, adiposity and aging
332. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men
333. Evidence of hypogonadism in massively obese males due to decreased free testosterone
334. Pathogenesis of the decreased androgen levels in obese men
335. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy
336. Visceral adiposity, androgens and plasma lipids in obese men
337. The endocrinology of obesity
338. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency and its relation to plasma androgens in hypogonadism of obese men
339. Androgens and estrogens in their negative feedback action in the hypothalamo-pituitary-testis axis: Site of action and evidence of their interaction
340. Divergent effects of the antiandrogen tamoxifen and of estrogens on luteinizing hormone(LH) pulse frequency, but not on basal LH levels and LH pulse amplitude in men
341. Androgen treatment of abdominally obese men
342. Additive effects of growth hormone and testosterone on lipolysis in adipocytes of hypophysectomized rats
343. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens
344. Induction of insulin resistance by androgens and estrogens
345. Endocrine aspects of obesity
346. Dual defects in pulsatile growth hormone secretion and clearence subserve the hyposomatotropism of obesity in man
347. Massive weight loss restores 24 hour growth hormone release profiles and serum insulin-like growth factor-1 levels in obese subjects
348. Free insulin-like growth factors in human obesity
349. The impact of obesity, fat distribution and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin and growth hormone
350. The role of growth hormone/insulin-like growth factors in adipocytie differentiation
351. Adipose tissue and muscle volume determination by computed tomography in Acromegaly before and 1 year after adenomectomy
352. Treatment of adults with growth hormone deficiency with recombinant human growth
353. Growth hormone vs. placebo teatment for one year in growth hormone deficient adults: Increase in exercise capacity and normalization of body composition
354. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response
355. Regional changes in adipose tissue flow and metabolism in rats after a meal
356. Neuroregulation of adipose tissue: Molecular and hormonal mechanisms
357. Metabolism of mammary, abdominal and femoral adipocytes in women before and after menopause
358. Regional adipose tissue metabolism in men and postmenopausal women
359. Gonadal steroid hormone regulation of the somatotropic axis during puberty in humans. Mechanisms of androgen and estrogen action